(1) Translational Research Laboratory, Catalan Institute of Oncology-IDIBELL, L’Hospitalet de Llobregat, Spain; (2) Department of Cell Death and Proliferation, Institute for Biomedical Research of Barcelona (IIBB-CSIC-IDIBAPS), Barcelona, Spain; (3) Unit of Infections and Cancer, Cancer Epidemiology ResearchProgramme, Catalan Institute of Oncology-IDIBELL, L’Hospitalet de Llobregat, Spain; (4) CIBERESP, L’Hospitalet de Llobregat, Spain; (5) Neurology Service, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Spain; (6) School of Biology, Chemistry and Health Science, and Faculty of Medical and Human Sciences, University of Manchester, Manchester, UK; (7) Department of Neurology, Stroke Unit, Hospital Universitari Mutua de Terrassa, Terrassa, Spain; (8) Fundacio IDIBELL, Barcelona, Spain

(1) Department of Respiratory Medicine, University Medical Center Utrecht, Utrecht, The Netherlands; (2) Current address: Promega Benelux, Leiden, The Netherlands

(1) Experimental Animal Laboratory, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA; (2) Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio, USA; (3) TA CV/GI, AstraZeneca R&D Mölndal, Mölndal, Sweden

(1) Department of Laboratory Medicine, University Medical Centre Groningen, University of Groningen, the Netherlands; (2) Division of Haemostasis and Thrombosis, Department of Haematology, University Medical Centre Groningen, University of Groningen, the Netherlands

(1) Deutsches Herzzentrum München, Munich, Germany

(1) Thrombosis & AtherosclerosisResearch Institute, Hamilton General Hospital, Ontario, Canada; (2) Division of Cardiology, McMaster University, Ontario, Canada; (3) Daiichi Sankyo Pharma Development, Edison, New Jersey, USA; (4) Daiichi Sankyo India (Private) Ltd., Chembur, Mumbai, India; (5) Pharsight Corporation, Mountain View, California, USA

(1) College of Public Health, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; (2) King’s College Hospital, London, UK; (3) Sahlgrenska University Hospital; (4) Thunder Bay Regional Hospital, Thunder Bay, Ontario, Canada; (5) Daiichi Sankyo Pharma Development, Edison, New Jersey, USA; (6) McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada

(1) Hospital Universitario Virgen de la Arrixaca, Universidad de Murcia, Murcia, Spain; (2) University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK; (3) Centro Regional de Hemodonación. Universidad de Murcia, Murcia, Spain; (4) Hospital General Universitario de Alicante, Alicante, Spain

(1) Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon; (2) Division of Neurology, Rafik Hariri University Hospital, Beirut, Lebanon; (3) Division of Neurology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon